Coloplast's stock price has declined by 25% since April 2023, making it more attractive but still overvalued based on fundamentals and valuation multiples. Recent quarterly results show revenue growth ...

Coloplast is now rated a cautious 'Buy,' as its valuation has become more reasonable after a significant price correction. Coloplast continues to deliver solid organic growth, boasts a wide economic ...

Coloplast historically has introduced consistent innovation in its ostomy-care products, including different types of adhesives, one- and two-piece devices, and irrigation systems. Finally, we note ...

Coloplast delivered Q4 organic growth of 8% and an EBIT margin1 of 26%, which was negatively impacted by extraordinary costs and currencies. Reported revenue in DKK grew 12% with 3%-pts contribution ...

Based in Denmark, Coloplast is a leader in global ostomy and continence care. The firm has made inroads into the concentrated urology and fragmented woundcare markets, but it remains a peripheral ...

Coloplast delivered 8% organic growth and an EBIT margin1 of 27% in Q1, in line with expectations. Reported revenue in DKK grew 6% and included negative impact from the divestment of Skin Care and ...